Beyond Biotech podcast 15: Cullinan Oncology, Pleco Therapeutics, TikoMed

02:17 Labiotech.eu news
04:59 TikoMed
09:20 Pleco Therapeutics
25:45 Cullinan Oncology/World Cancer Research Day
44:15 JLL

This week’s podcast has three guests. In honor of World Cancer Research Day on September 24, we have an overview of cancer research with Nadim Ahmed, CEO of Cullinan Oncology; a chat with Ivo Timmermans, CEO of Pleco Therapeutics; and talk with Anders Kristensson, CEO of TikoMed.

We also have our weekly chat with global commercial real estate services company JLL, with Travis McCready. 

This week’s podcast is sponsored by Single Use Support, the end-to-end process solution provider for fluid management.

World Cancer Research Day: Support research to prevent cancer and catch it early

For seven consecutive years, the international research community is marking World Cancer Research Day (WCRD) on September 24, a global movement that seeks to raise awareness of the importance of cancer research to increase survival, facilitate access to scientific advances worldwide and reduce the global burden of cancer. 

This year, experts in the field of oncology and cancer researchers will focus on cancer health disparities, particularly in the areas of prevention and early detection research and care. The motto this year is Support research to prevent cancer and catch it early.

Cullinan Oncology

To talk about the current state of cancer research, we spoke with Nadim Ahmed, CEO of Cullinan Oncology.

Cullinan Oncology is a biopharmaceutical company dedicated to creating new standards of care for patients with cancer. It finds the most promising clinic-ready cancer therapies through its own discovery efforts and engagement with academic and industry partners. 

Pleco Therapeutics raises €17.3M to develop AML product

Pleco Therapeutics BV, a specialty biopharma company in the Netherlands developing novel treatments designed to detoxify the cancer micro-environment has raised total funds of $17.2 million in series A financing. 

The funds will be used to complete development of, and to commercialize, the company’s novel lead Plecoid product, PTX-061, to improve the effectiveness of chemotherapy in patients with acute myeloid leukaemia (AML).

Pleco’s technology provides a platform for the development of a pipeline of therapies. In addition to PTX-061 for AML, the current pipeline includes additional candidates in preclinical testing for the treatment of other rare diseases such as SCLC.

Research shows TikoMed’s ILB can treat neurodegenerative diseases including ALS

Peer-review research published in Frontiers in Pharmacology supports the broad spectrum mechanism of action of Swedish biopharma company TikoMed’s ILB neuroprotective drug platform. 

In multiple preclinical and clinical studies across a variety of neuroinflammation-driven diseases, the low molecular weight dextran sulfate compound both mobilized and modulated naturally occurring tissue repair mechanisms and restored cellular homeostasis and function by releasing heparin-binding growth factors. 

Sponsor
Interested in sponsoring one or more episodes of the podcast? Learn more here!

Leave a review on Apple podcasts
Reviews are hugely important because they help new people discover this podcast. If you enjoyed listening to this episode, we would love to hear your feedback!

Connect with us
labiotech.eu
Subscribe to our newsletter